Scientific Sales Executive
Opella is seeking a Scientific Sales Executive in Vishakapatnam to drive OTC and VMS brand sales within the healthcare sector. The role involves increasing prescriptions through doctor engagement, managing regional inventory, and implementing marketing activities to meet sales targets. Candidates must have at least 2 years of experience in pharmaceuticals or consumer health, along with strong influencing and communication skills. The position focuses on market intelligence, product availability, and professional relationship building with medical practitioners and retailers.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
2+ years
Function
Sales
Work mode
Onsite, India
Company
Tier 2
What you will work on
Opella is seeking a Scientific Sales Executive in Vishakapatnam to drive OTC and VMS brand sales within the healthcare sector. The role involves increasing prescriptions through doctor engagement, managing regional inventory, and implementing marketing activities to meet sales targets. Candidates must have at least 2 years of experience in pharmaceuticals or consumer health, along with strong influencing and communication skills. The position focuses on market intelligence, product availability, and professional relationship building with medical practitioners and retailers.
TAL's take
Role is well-defined with clear KPIs in an established global company, though lacks technical complexity and is a traditional field sales position.
The JD provides extremely granular details on responsibilities, internal/external stakeholders, and performance metrics, leaving no ambiguity about the daily tasks.
Salaries at Opella
36.0 LPA average
Based on 1 Grapevine salary entries for Opella.
Other roles
10 - 12 years | CL3
36 LPA average
Range: 36 - 36 LPA
Must haves
- 2+ years of relevant experience
- Any Graduate degree, preferably B.Sc or B.Pharma
- Knowledge of pharmaceutical industry
- Basic financial management skills
- Excellent oral and verbal communication skills
- Proficiency in MS Office
Tools and skills
About the company
Opella is a global consumer health company; while a major subsidiary, it falls under the established mid-stage/subsidiary category in the context of Indian tech hiring.
Posts mentioning Opella
How is Opella Health care for joining as SAP cobsultant with 8 + Experince.
Please suggest is Opella Healthcare is good for SAP consultants,i did google getting 50 50 review for pros and cons..
Recent Resignations
Notable executive departures disclosed in the past week include: Both Co-CEOs of Sprinklr (NYSE: CXM — $1.92 billion) “mutually agreed” to depart after five months and fifteen years, respectively; they were replaced by an outside candidate who was previously CEO of Vonage. In February, the company’s Chief Revenue Officer “stepped down” after a little over one year. The company is down ~65% since its June 2021 IPO. CFO of Openlane (NYSE: KAR — $2.11 billion), formerly KAR Auction Services, “will resign from the company effective March 1, 2025 to pursue another opportunity closer to family” after two years. CEO of Sun Communities (NYSE: SUI — $15.6 billion) “has informed the board of his intention to retire in 2025” after 32 years and the board has “established a CEO Succession Planning Committee.” In September 2024, Blue Orca Capital called the company “a mess of egregious executive behavior” and found that Sun’s CEO “received an undisclosed $4 million loan from the family of a supposedly independent Director who sits on the Audit Committee” and also separately “admitted borrowing $700K from a director whose law firm also serves as [Sun’s] general counsel.” Chief Operating Officer of DXC Technology (NYSE: DXC — $3.92 billion) “will be exiting the company” after nearly two years. The company’s General Counsel also departed in March and the company’s former CEO stepped down in December 2023. Chief Commercial Officer of QuidelOrtho Corp (NASDAQ: QDEL — $2.94 billion) was “terminated” after two and a half years along with the company’s Chief Operating Officer who was “terminated” after four years. In February, the company’s CEO was also “terminated” after fifteen years. Chief Accounting Officer of Hippo Holdings (NYSE: HIPO — $701 million) “entered into a separation agreement” after a little over three years. In October, the company’s Chief Revenue Officer also departed after four years. In March 2023, the company replaced Ernst & Young as its a